Citizens Jmp Issues Pessimistic Forecast for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price objective dropped by stock analysts at Citizens Jmp from $146.00 to $137.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has a “market outperform” rating on the stock. Citizens Jmp’s target price would suggest a potential upside of 36.12% from the company’s previous close.

MIRM has been the topic of several other reports. TD Cowen increased their price objective on Mirum Pharmaceuticals from $125.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Wolfe Research initiated coverage on Mirum Pharmaceuticals in a research report on Tuesday, May 19th. They issued an “outperform” rating and a $145.00 target price for the company. Weiss Ratings cut shares of Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. Royal Bank Of Canada raised their price target on shares of Mirum Pharmaceuticals from $142.00 to $148.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Finally, Robert W. Baird lifted their price target on shares of Mirum Pharmaceuticals from $112.00 to $129.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $137.33.

Mirum Pharmaceuticals Stock Performance

MIRM stock opened at $100.65 on Thursday. The stock has a market capitalization of $6.14 billion, a PE ratio of -6.92 and a beta of 0.52. Mirum Pharmaceuticals has a 12-month low of $57.79 and a 12-month high of $130.00. The company has a current ratio of 2.86, a quick ratio of 1.99 and a debt-to-equity ratio of 1.28. The stock’s 50 day simple moving average is $110.33 and its 200 day simple moving average is $101.79.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The business had revenue of $176.24 million for the quarter, compared to analysts’ expectations of $166.33 million. During the same quarter in the prior year, the business posted ($0.12) earnings per share. The business’s revenue for the quarter was up 37.9% on a year-over-year basis. As a group, research analysts forecast that Mirum Pharmaceuticals will post -2.01 earnings per share for the current fiscal year.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 5,000 shares of the stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $122.25, for a total value of $611,250.00. Following the transaction, the chief financial officer owned 42,181 shares of the company’s stock, valued at approximately $5,156,627.25. This represents a 10.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 1,840 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $105.29, for a total value of $193,733.60. Following the completion of the transaction, the senior vice president directly owned 1,274 shares in the company, valued at $134,139.46. The trade was a 59.09% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 67,155 shares of company stock worth $7,185,662. 8.32% of the stock is owned by insiders.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in MIRM. Janus Henderson Group PLC increased its holdings in Mirum Pharmaceuticals by 14.5% during the first quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock valued at $641,764,000 after buying an additional 880,505 shares during the last quarter. BlackRock Inc. purchased a new position in shares of Mirum Pharmaceuticals during the 2nd quarter worth $513,945,000. Vanguard Group Inc. boosted its stake in shares of Mirum Pharmaceuticals by 2.0% during the 4th quarter. Vanguard Group Inc. now owns 2,596,089 shares of the company’s stock worth $205,065,000 after acquiring an additional 50,720 shares during the last quarter. State Street Corp grew its position in shares of Mirum Pharmaceuticals by 59.2% during the 4th quarter. State Street Corp now owns 2,143,992 shares of the company’s stock valued at $169,354,000 after acquiring an additional 797,088 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Mirum Pharmaceuticals by 10.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,420,375 shares of the company’s stock valued at $112,196,000 after acquiring an additional 137,087 shares during the period.

More Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Second-quarter revenue reached $176.24 million, beating the $166.33 million consensus estimate and rising 37.9% year over year. Growth was driven by Livmarli and Mirum’s other bile-acid therapies. Management also raised its 2026 sales outlook, providing a favorable signal about demand and the company’s commercial trajectory. Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts remain broadly constructive despite reducing their targets. TD Cowen lowered its target to $140 and retained a “buy” rating; Citizens JMP cut its target to $137 but maintained “market outperform”; and HC Wainwright reduced its target to $140 while keeping a “buy” rating. These targets imply substantial potential upside from recent trading levels.
• Neutral Sentiment: Mirum reported a quarterly loss of $1.06 per share, wider than the $0.74 consensus loss and the $0.12 loss recorded a year earlier. The loss reflects continued investment in the company’s rare-disease pipeline, but it remains a near-term valuation concern. Mirum’s Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
• Negative Sentiment: Citizens warned that an “unexpected” FDA request for a Phase 3 study clouds Mirum’s near-term outlook. The additional regulatory requirement could delay development or approval plans, increase spending, and weigh on investor sentiment.
• Negative Sentiment: Senior Vice President Jolanda Howe sold 1,840 shares worth approximately $193,734, reducing her direct holdings by 59.1%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which lessens its signaling value, but the sale still adds a modest negative headline.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.